retatrutide fat loss clinical trial Retatrutide, an Amazing Future for Weight Tirzepatide vs. Retatrutide: Key Differences

Atherosclerosis (2015) 240(1):2509

Debunking Common GLP-1 Myths GLP-1s dont address the root cause of obesity. Wrong

Obesity is also a major health concern, with more than one-third of American adults considered obese 2

Many of the cardiovascular and metabolic trials informing the discussion were not designed to evaluate ophthalmic outcomes. The authors called for prospective ophthalmology-specific studies incorporating imaging biomarkers, visual outcomes and disease-specific monitoring, noting that parsing the protective benefits or adverse effects of this rapidly growing medication class will be essential to refining disease management and improve patient outcomes. As GLP-1 therapies become increasingly common among patients with diabetes, obesity and vascular comorbiditiesprecisely the populations populating ophthalmic clinicsthe field may not have the luxury of waiting for cleaner data

The magnitude of energy expenditure increase ranges from 5-10% above baseline depending on dose and individual responsiveness

Features and development of Coot